Hamlet BioPharma Manufactures Alpha1H Batch to Phase III Quality Standards
Hamlet BioPharma has produced and released its first batch of Alpha1H meeting Phase III clinical trial quality standards. The drug will be distributed to clinical trial sites.
Hamlet BioPharma announced on June 25, 2026, that it has produced and released its first batch of Alpha1H conforming to the quality requirements for Phase III clinical trials. This batch is intended for use in the company's ongoing clinical studies for bladder cancer.
The successful production, meeting Phase III quality standards, marks a significant step toward the potential commercialization of Alpha1H. The company previously announced an expansion of its clinical trials into the United States in collaboration with the University of Iowa. These trials focus on treating high-risk, resistant, non-muscle-invasive bladder cancer.
Hamlet BioPharma is developing Alpha1H as a treatment for bladder cancer. The company's novel antibiotic-free anti-infective therapies have also garnered attention, with publications in journals such as The Journal of Infectious Diseases.
The company also maintains active investor relations through regular digital investor meetings. An upcoming meeting is scheduled for June 30, 2026.